• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于注意缺陷/多动障碍儿童及青少年的Weiss功能损害评定量表家长报告表的心理测量学验证

Psychometric validation of the Weiss Functional Impairment Rating Scale-Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorder.

作者信息

Gajria Kavita, Kosinski Mark, Sikirica Vanja, Huss Michael, Livote Elayne, Reilly Kathleen, Dittmann Ralf W, Erder M Haim

机构信息

Shire, 725 Chesterbrook Boulevard, Wayne, PA, 19087, USA.

QualityMetric Incorporated, 24 Albion Road, Building 400, Lincoln, RI, 02865, USA.

出版信息

Health Qual Life Outcomes. 2015 Nov 17;13:184. doi: 10.1186/s12955-015-0379-1.

DOI:10.1186/s12955-015-0379-1
PMID:26577642
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4650258/
Abstract

BACKGROUND

Measurement properties of the Weiss Functional Impairment Rating Scale-Parent Report Form (WFIRS-P), which assesses attention-deficit/hyperactivity disorder (ADHD)-related functional impairment in children/adolescents (6-17 years), were examined.

METHODS

Data from seven randomized, controlled trials were pooled. Analyses were conducted in two random half-samples. WFIRS-P conceptual framework was evaluated using confirmatory factor analyses (CFA). Reliability was estimated using internal consistency (Cronbach's alpha) and test-retest reliability methods. Convergent validity was assessed using correlations between WFIRS-P domain scores and the ADHD-RS-IV and Clinical Global Impression-Severity (CGI-S) scales. Responsiveness was tested by comparing mean changes in WFIRS-P domain scores between responders and non-responders based on clinical criteria.

RESULTS

CFA adequately confirmed the item-to-scale relationships defined in the WFIRS-P conceptual framework. Cronbach's alpha coefficient exceeded 0.7 for all domains and test-retest reliability exceeded 0.7 for all but Risky Activities. With few exceptions, WFIRS-P domains correlated significantly (p < 0.05) with ADHD-RS-IV Total, Inattention and Hyperactivity-Impulsivity scores and CGI-S at baseline and follow-up in both random half-samples. Mean changes in WFIRS-P domain scores differed significantly between responder and non-responder groups in the expected direction (p < 0.001).

CONCLUSIONS

Study results support the reliability, validity and responsiveness of the WFIRS-P. Findings were replicated between two random samples, further demonstrating the robustness of results.

摘要

背景

对Weiss功能损害评定量表家长报告表(WFIRS-P)的测量属性进行了检验,该量表用于评估儿童/青少年(6 - 17岁)与注意力缺陷多动障碍(ADHD)相关的功能损害。

方法

汇总了七项随机对照试验的数据。在两个随机的半样本中进行分析。使用验证性因子分析(CFA)评估WFIRS-P概念框架。使用内部一致性(Cronbach's α)和重测信度方法估计信度。通过比较WFIRS-P领域得分与ADHD-RS-IV和临床总体印象严重程度(CGI-S)量表之间的相关性来评估收敛效度。根据临床标准,通过比较反应者和无反应者之间WFIRS-P领域得分的平均变化来测试反应性。

结果

CFA充分证实了WFIRS-P概念框架中定义的项目与量表的关系。所有领域的Cronbach's α系数均超过0.7,除“危险活动”外,所有领域的重测信度均超过0.7。在两个随机半样本的基线和随访中,除少数例外,WFIRS-P领域与ADHD-RS-IV总分、注意力不集中和多动冲动得分以及CGI-S均有显著相关性(p < 0.05)。反应者和无反应者组之间WFIRS-P领域得分的平均变化在预期方向上有显著差异(p < 0.001)。

结论

研究结果支持WFIRS-P的信度、效度和反应性。结果在两个随机样本中得到重复,进一步证明了结果的稳健性。

相似文献

1
Psychometric validation of the Weiss Functional Impairment Rating Scale-Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorder.用于注意缺陷/多动障碍儿童及青少年的Weiss功能损害评定量表家长报告表的心理测量学验证
Health Qual Life Outcomes. 2015 Nov 17;13:184. doi: 10.1186/s12955-015-0379-1.
2
Psychometric properties of the Weiss Functional Impairment Rating Scale parent and self-reports in a Norwegian clinical sample of adolescents treated for ADHD.挪威 ADHD 青少年临床样本中 Weiss 功能障碍评定量表父母报告和自评的心理测量特性。
Nord J Psychiatry. 2021 Jan;75(1):63-72. doi: 10.1080/08039488.2020.1795252. Epub 2020 Aug 4.
3
Psychometric properties of a modified version of the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P) in a clinical sample of children with aggressive behavior.中文版威氏功能损伤评定量表家长报告修订版(WFIRS-P)在具有攻击性行为的临床儿童样本中的心理测量学特性。
Qual Life Res. 2019 Jan;28(1):241-251. doi: 10.1007/s11136-018-2015-0. Epub 2018 Oct 1.
4
Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.缓释胍法辛对注意缺陷/多动障碍儿童功能损害有何影响?一项随机对照试验的结果。
CNS Drugs. 2015 Nov;29(11):953-62. doi: 10.1007/s40263-015-0291-6.
5
Psychometric properties of the Japanese version of the Weiss Functional Impairment Rating Scale: Self-Report.日本版维斯功能损害评定量表:自评的心理测量学特性。
Atten Defic Hyperact Disord. 2017 Sep;9(3):169-177. doi: 10.1007/s12402-016-0213-6. Epub 2016 Dec 24.
6
Descriptive and psychometric properties of the Persian version of the Weiss functional impairment rating scale: parent report form in Iranian children.魏氏功能损伤评定量表波斯语版(家长报告版)在伊朗儿童中的描述性和心理计量学特性。
Health Qual Life Outcomes. 2018 Dec 7;16(1):225. doi: 10.1186/s12955-018-1053-1.
7
Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.将注意力缺陷多动障碍评定量表-5 和 Weiss 功能障碍评定量表-父母效能评分转换为 SPN-812(维洛沙嗪缓释片)在儿童和青少年注意力缺陷多动障碍四项随机临床试验中的临床总体印象临床显著度水平。
J Child Adolesc Psychopharmacol. 2021 Apr;31(3):214-226. doi: 10.1089/cap.2020.0148. Epub 2021 Feb 17.
8
Turkish validity and reliability study of the Weiss Functional Impairment Rating Scale-Parent Report.Weiss功能损害评定量表家长报告的土耳其语效度和信度研究。
Atten Defic Hyperact Disord. 2015 Jun;7(2):129-39. doi: 10.1007/s12402-014-0158-6. Epub 2014 Nov 27.
9
Validation of the Weiss Functional Impairment Rating Scale (WFIRS-P) as a Functional Impairment Measure in a General Population of Schoolchildren.验证 Weiss 功能障碍评定量表(WFIRS-P)作为一般学龄儿童人群的功能障碍测量工具的有效性。
Assessment. 2023 Dec;30(8):2533-2544. doi: 10.1177/10731911231154501. Epub 2023 Feb 17.
10
Functional impairment outcomes in clinical trials of different ADHD medications: post hoc responder analyses and baseline subgroup analyses.不同 ADHD 药物临床试验中的功能障碍结局:事后应答者分析和基线亚组分析。
Eur Child Adolesc Psychiatry. 2021 May;30(5):809-821. doi: 10.1007/s00787-020-01586-5. Epub 2020 Jul 20.

引用本文的文献

1
Subtypes of tic disorders in children and adolescents: based on clinical characteristics.儿童和青少年抽动障碍的亚型:基于临床特征
BMC Pediatr. 2025 May 2;25(1):349. doi: 10.1186/s12887-025-05698-2.
2
Vitamin D insufficiency and sleep disturbances in children with ADHD: a case-control study.注意力缺陷多动障碍患儿的维生素D缺乏与睡眠障碍:一项病例对照研究。
Front Psychiatry. 2025 Mar 20;16:1546692. doi: 10.3389/fpsyt.2025.1546692. eCollection 2025.
3
Daily functioning and (health-related) quality of life of young adult survivors of childhood bacterial meningitis.儿童细菌性脑膜炎后青年幸存者的日常功能和(健康相关)生活质量。
Eur J Pediatr. 2024 Dec;183(12):5441-5453. doi: 10.1007/s00431-024-05819-6. Epub 2024 Oct 18.
4
Executive Functioning Profiles in Neurodevelopmental Disorders: Parent-Child Outcomes.神经发育障碍中的执行功能概况:亲子结果
Children (Basel). 2024 Jul 27;11(8):909. doi: 10.3390/children11080909.
5
Retrospective Study on the Therapeutic Effect of Repetitive Transcranial Magnetic Stimulation Combined with Tiapride Hydrochloride Tablets in Children with Attention Deficit Hyperactivity Disorder.重复经颅磁刺激联合盐酸硫必利片治疗儿童注意缺陷多动障碍的疗效回顾性研究
Alpha Psychiatry. 2024 Jun 1;25(3):382-387. doi: 10.5152/alphapsychiatry.2024.231442. eCollection 2024 Jun.
6
Long-term medication for ADHD (LMA) trial: 2-year prospective observational study in children and adolescents. Core symptoms, daily functioning, and comorbidity outcomes.ADHD 长期药物治疗(LMA)试验:儿童和青少年 2 年前瞻性观察研究。核心症状、日常功能和合并症结局。
Eur Arch Psychiatry Clin Neurosci. 2024 Jun;274(4):879-890. doi: 10.1007/s00406-023-01744-1. Epub 2024 Jan 27.
7
Efficacy and Safety of SPN-812 (Extended-Release Viloxazine) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis.SPN-812(缓释盐酸维洛沙嗪)治疗儿童和青少年注意力缺陷多动障碍的疗效与安全性:一项系统评价和Meta分析
Brain Sci. 2023 Nov 24;13(12):1627. doi: 10.3390/brainsci13121627.
8
Network Analysis of ADHD Symptoms and Cognitive Profiles in Children.儿童注意力缺陷多动障碍症状与认知特征的网络分析
Neuropsychiatr Dis Treat. 2023 May 18;19:1207-1219. doi: 10.2147/NDT.S409503. eCollection 2023.
9
Real-World Efficacy and Safety of Extended-Release Methylphenidate (PRC-063) in the Treatment of ADHD in Pediatric and Adult Subjects: Results of a Phase IV Multicenter Comparison With Lisdexamfetamine Dimesylate.真实世界中 PRC-063 缓释哌甲酯治疗儿童和成人 ADHD 的疗效和安全性:与赖氨酸安非他命二甲酸盐的 IV 期多中心比较结果。
J Atten Disord. 2023 May;27(7):743-756. doi: 10.1177/10870547231172767. Epub 2023 May 5.
10
Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree ): A post hoc analysis of four randomized clinical trials of children and adolescents with attention-deficit/hyperactivity disorder.维洛沙嗪缓释胶囊(Qelbree)治疗儿童和青少年注意缺陷多动障碍的四项随机临床试验的事后分析:同伴关系和社交活动的反应。
Brain Behav. 2023 Apr;13(4):e2910. doi: 10.1002/brb3.2910. Epub 2023 Feb 27.

本文引用的文献

1
A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.一项随机、安慰剂对照试验研究胍法辛缓释剂治疗青少年注意缺陷多动障碍。
J Am Acad Child Adolesc Psychiatry. 2015 Nov;54(11):916-25.e2. doi: 10.1016/j.jaac.2015.08.016. Epub 2015 Sep 15.
2
Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design.伴有注意缺陷多动障碍的儿童和青少年中麦盐酸赖氨酸的疗效维持:随机撤药研究设计。
J Am Acad Child Adolesc Psychiatry. 2014 Jun;53(6):647-657.e1. doi: 10.1016/j.jaac.2014.01.017. Epub 2014 Mar 4.
3
Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.随机、双盲试验研究胍法辛缓释剂治疗注意缺陷多动障碍儿童:早晨或晚上给药。
J Am Acad Child Adolesc Psychiatry. 2013 Sep;52(9):921-30. doi: 10.1016/j.jaac.2013.06.006. Epub 2013 Aug 1.
4
Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.二甲磺酸赖右苯丙胺和托莫西汀治疗注意缺陷多动障碍的疗效与安全性:一项头对头、随机、双盲、IIIb期研究
CNS Drugs. 2013 Dec;27(12):1081-92. doi: 10.1007/s40263-013-0104-8.
5
Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder.一项随机对照研究中儿童和青少年注意缺陷多动障碍患者使用赖氨酸右旋苯丙胺二甲硫酸盐的健康相关生活质量和功能结局。
CNS Drugs. 2013 Oct;27(10):829-40. doi: 10.1007/s40263-013-0095-5.
6
A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.一项关于二甲磺酸赖右苯丙胺治疗青少年注意力缺陷/多动障碍的长期开放标签安全性和有效性试验。
J Child Adolesc Psychopharmacol. 2013 Feb;23(1):11-21. doi: 10.1089/cap.2011.0088.
7
European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.一项针对儿童和青少年注意缺陷多动障碍的 lisdexamfetamine dimesylate 的欧洲、随机、3 期研究。
Eur Neuropsychopharmacol. 2013 Oct;23(10):1208-18. doi: 10.1016/j.euroneuro.2012.11.012. Epub 2013 Jan 15.
8
Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.Lisdexamfetamine dimesylate 在成人注意缺陷多动障碍中的疗效维持:随机撤药设计。
J Clin Psychiatry. 2012 Jul;73(7):977-83. doi: 10.4088/JCP.11m07430. Epub 2012 Jun 12.
9
Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.一项组胺 H3 受体拮抗剂治疗成人注意缺陷多动障碍的随机临床试验。
CNS Drugs. 2012 May 1;26(5):421-34. doi: 10.2165/11631990-000000000-00000.
10
A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.一项关于胍法辛缓释剂和精神兴奋剂治疗注意缺陷/多动障碍的对照试验。
J Am Acad Child Adolesc Psychiatry. 2012 Jan;51(1):74-85.e2. doi: 10.1016/j.jaac.2011.10.012. Epub 2011 Nov 25.